Sun Pharma schedules analyst meetings in Mumbai for August 2026
Sun Pharmaceutical Industries Limited has scheduled a series of physical investor meetings in Mumbai for August 2026. Engagements include sessions with Nirmal Bang, Emkay Confluence, and Equirus. The company confirmed that no unpublished price-sensitive information will be disclosed during these interactions.
*this image is generated using AI for illustrative purposes only.
Sun Pharmaceutical Industries Limited has announced a schedule of upcoming analyst and institutional investor meetings to be held in Mumbai during August 2026. The company will engage with market participants through both group and one-on-one sessions at three major financial conferences. This disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency regarding management’s interaction with the investment community.
The meetings are scheduled across three dates in early August, allowing analysts and investors to discuss business outlooks and industry trends. Sun Pharmaceutical Industries Limited emphasized that no Unpublished Price Sensitive Information (UPSI) will be disclosed at any of these events. The schedule remains subject to change due to exigencies on either side.
Meeting Schedule
The following table outlines the confirmed engagements:
| Date | Analyst/Investor/Event | Venue | Type of Meeting |
|---|---|---|---|
| 10-Aug-26 | Nirmal Bang Institutional Equities, Business Outlook & Leading Through Volatility | Mumbai | Physical (Group & One-on-one) |
| 12-Aug-26 | Emkay Confluence 2026 India: Full Throttle Ahead | Mumbai | Physical (Group & One-on-one) |
| 13-Aug-26 | Equirus: Annual India Conference 26 | Mumbai | Physical (Group & One-on-one) |
Compliance Details
The intimation was signed by Anoop Deshpande, Company Secretary and Compliance Officer of Sun Pharmaceutical Industries Limited. The disclosure was filed on August 05, 2026, with the National Stock Exchange of India Limited and BSE Limited. The company reaffirmed its commitment to regulatory compliance by explicitly stating that all interactions would adhere to SEBI guidelines regarding information symmetry.
Historical Stock Returns for Sun Pharmaceutical
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.12% | -1.09% | +0.34% | +13.71% | +20.74% | +144.78% |
How might Sun Pharma's engagement at these August 2026 conferences influence its stock valuation in the immediate quarter following the events?
What specific regulatory or patent cliff challenges is Sun Pharma likely to address with institutional investors given the 2026 timeline?
Will the insights shared during these meetings signal any strategic shifts in Sun Pharma's R&D pipeline or international expansion plans?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
